

Impact of changing spectrum of infectious diseases on lexicon.

Ritz Skinner*

Department of Microbiology, Debre Tabor University, Debre Tabor, Ethiopia

Introduction

In recent years, we have witnessed a shift in the spectrum of infectious diseases. Emerging diseases, re-emerging diseases, and antibiotic resistance have all had a significant impact on global health. The lexicon of infectious diseases has also evolved as new diseases have emerged and others have become more prevalent. This article will explore the impact of changing infectious disease spectra on the lexicon. One of the most significant changes in the infectious disease spectrum has been the emergence of new diseases. The emergence of new diseases often leads to the creation of new medical terms. For example, the term SARS (Severe Acute Respiratory Syndrome) was created in 2003 to describe a newly emerging infectious disease. Similarly, the term MERS (Middle East Respiratory Syndrome) was created in 2012 to describe another newly emerging infectious disease. These terms quickly became part of the medical lexicon and were used to describe these new diseases [1].

The emergence of new diseases has also led to the creation of new acronyms. Acronyms are often used to simplify the name of a disease or a group of diseases. For example, HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immunodeficiency Syndrome) are both acronyms that are used to describe a group of diseases caused by the same virus. Similarly, the acronym COVID-19 (Coronavirus Disease 2019) was created to describe the disease caused by the SARS-CoV-2 virus. Acronyms are useful because they make it easier to communicate about diseases, especially when discussing them in the media or with the general public [2].

The changing spectrum of infectious diseases has also led to the re-emergence of some diseases that were previously thought to be under control. For example, tuberculosis (TB) was thought to be under control in the 1960s and 1970s, but it has since re-emerged as a major global health threat. The re-emergence of TB has led to the development of new terms such as MDR-TB (Multi-Drug Resistant Tuberculosis) and XDR-TB (Extensively Drug Resistant Tuberculosis). These terms are used to describe strains of TB that are resistant to multiple drugs, making them more difficult to treat [3].

The re-emergence of infectious diseases has also led to the development of new treatments and therapies. For example, the emergence of drug-resistant tuberculosis has led to the development of new drugs such as bedaquiline

and delamanid. These drugs are used to treat drug-resistant TB and have become part of the medical lexicon. Another significant change in the infectious disease spectrum has been the increasing prevalence of antibiotic-resistant bacteria. Antibiotic resistance is a major global health threat and has led to the development of new terms such as MRSA (Methicillin-Resistant *Staphylococcus Aureus*) and CRE (Carbapenem-Resistant *Enterobacteriaceae*). These terms are used to describe bacteria that are resistant to multiple antibiotics and are difficult to treat. The increasing prevalence of antibiotic-resistant bacteria has also led to the development of new treatment strategies such as the use of phage therapy and the development of new antibiotics [4].

The changing spectrum of infectious diseases has also had an impact on public health messaging. Public health messaging is an important part of controlling infectious diseases, and the lexicon used in public health messaging has evolved as the spectrum of infectious diseases has changed. For example, in the early days of the HIV epidemic, public health messages focused on promoting safe sex and condom use. More recently, public health messages have focused on promoting the use of PrEP (Pre-Exposure Prophylaxis) to prevent HIV transmission [5].

The development of new treatment strategies and the use of new terms to describe drug-resistant bacteria have highlighted the need for more research and development in the field of infectious diseases. The use of phage therapy and the development of new antibiotics are examples of how the medical community is working to combat antibiotic resistance and the prevalence of drug-resistant bacteria. These new treatments and therapies require new terms and acronyms to describe them, which further contributes to the evolving lexicon of infectious diseases.

Conclusion

The impact of changing infectious disease spectra on the lexicon has been significant. New diseases, the re-emergence of old ones, and the prevalence of antibiotic resistance have all contributed to the development of new terms and acronyms, as well as the use of new treatment strategies. The evolving lexicon has also affected public health messaging, which plays a critical role in controlling the spread of infectious diseases. As the infectious disease spectrum continues to change, we can expect the lexicon to evolve further, requiring continued adaptation and education.

*Correspondence to: Ritz Skinner. Department of Microbiology, Debre Tabor University, Debre Tabor, Ethiopia, E-mail: skinner.ritz@gmail.com

Received: 29-Jul-2023, Manuscript No. AAMCR-23-109587; Editor assigned: 03-Aug-2023, Pre QC No. AAMCR-23-109587(PQ); Reviewed: 15-Aug-2023, QC No. AAMCR-23-109587;

Revised: 22-Aug-2023, Manuscript No. AAMCR-23-109587(R); Published: 30-Aug-2023, DOI: 10.35841/aamcr-7.4.163

References

1. Casadevall A, Pirofski LA. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. *Infect Immun*. 1999;67(8):3703-13.
2. Cheng KJ, Irvin RT, Costerton JW. Autochthonous and pathogenic colonization of animal tissues by bacteria. *Can J Microbiol*. 1981;27(5):461-90.
3. Finland M. Changing ecology of bacterial infections as related to antibacterial therapy. *J Infect Dis*. 1970;122(5):419-31.
4. Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease. *Infect Immun*. 2000;68(12):6511-8.
5. Smith H. The revival of interest in mechanisms of bacterial pathogenicity. *Biol Rev Camb Philos Soc*. 1995;70(2):277-316.